Categories AlphaGraphs, Analysis, Health Care
Viking Therapeutics earnings preview: All eyes on NASH
Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market expects the company to report a loss of 10 cents per share during the quarter, narrower than the 14 cents per share loss it reported in the same period last year.
During the year-over quarter, net loss had increased by 14%, hurt by higher research and development expenses. As we head into the fourth quarter of this year, the clinical-stage biopharmaceutical firm is expected to see further growth in R&D expenses, which in turn, would weigh on results.
VKTX shares have gained 30% in the trailing 52 weeks. However, it has declined 60% since hitting a record peak in September last year.
Investors will be looking forward to any updates regarding the ongoing research on nonalcoholic steatohepatitis (NASH), a liver disease. Last month, Viking shares had jumped 6% after it was reported that rival Gilead Sciences’ (GILD) NASH candidate failed to meet its primary endpoint.
The stock once again received a bump when peer firm Intercept Pharmaceuticals (ICPT) produced positive topline results from the phase 3 study for its NASH drug. According to DelveInsight, the NASH market will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to $30.1 billion by 2028.
The stock has a 12-month average price target of $23, which represents a 193% upside from the last close. Hence the scope for a rally is high if the California-based firm pleases investors.
Earnings Transcript: Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Colgate-Palmolive (CL) Q3 2024 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its third quarter 2024 earnings results today. Net sales increased 2.4% year-over-year to $5 billion. Organic sales grew 6.8%. Net income attributable to Colgate-Palmolive Company was $737
Key takeaways from Southwest Airlines’ (LUV) Q3 2024 earnings report
Shares of Southwest Airlines Co. (NYSE: LUV) were down over 4% on Thursday. The stock has gained 4% over the past three months. The airline reported its earnings results for
HOG Earnings: A snapshot of Harley-Davidson’s Q3 2024 results
Motorcycle manufacturer Harley-Davidson (NYSE: HOG) Thursday reported a sharp fall in sales and net profit for the third quarter of 2024 amid weak demand. Consolidated net income declined to $119